Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double-blind placebo-controlled study
Article first published online: 7 SEP 2004
Volume 59, Issue 10, pages 1097–1101, October 2004
How to Cite
Smith, T. R. F., Alexander, C., Kay, A. B., Larché, M. and Robinson, D. S. (2004), Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double-blind placebo-controlled study. Allergy, 59: 1097–1101. doi: 10.1111/j.1398-9995.2004.00601.x
- Issue published online: 7 SEP 2004
- Article first published online: 7 SEP 2004
- Accepted for publication 3 March 2004
- cat allergen;
- CD4+CD25+ T regulatory cells;
- peptide immunotherapy;
- T cells
Background: We have previously described both modification of allergen immunotherapy using peptide fragments, and reduced regulation of allergen stimulated T cells by CD4+ CD25+ T cells from allergic donors when compared with nonallergic controls. It has been suggested that allergen immunotherapy induces regulatory T cell activity: we hypothesized that allergen peptide immunotherapy might increase suppressive activity of CD4+ CD25+ T cells.
Objective: To examine cat allergen-stimulated CD4 T cell responses and their suppression by CD4+ CD25+ T cells before and after cat allergen peptide immunotherapy in a double-blind placebo-controlled study.
Methods: Peripheral blood was obtained and stored before and after peptide immunotherapy or placebo treatment. CD4+ and CD4+ CD25+ were then isolated by immunomagnetic beads and cultured with allergen in vitro.
Results: Comparing cells from blood taken before with that after peptide immunotherapy there was a significant reduction in both proliferation and IL-13 production by allergen-stimulated CD4+ T cells, whereas no change was seen after placebo. CD4+ CD25+ T cells suppressed both proliferation and IL-13 production by CD4+ CD25− T cells before and after therapy but peptide therapy was not associated with any change in suppressive activity of these cells.
Conclusion: Allergen peptide immunotherapy alters T cell response to allergen through mechanisms other than changes in CD4+ CD25+ T cell suppression.